help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saltz, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saltz, L. B.
The Oncologist, Vol. 2, No. 6, 402–409, December 1997
© 1997 AlphaMed Press

Clinical Use of Irinotecan:Current Status and Future Considerations

Leonard B. Saltz

Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Correspondence: Leonard B. Saltz, M.D., Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA. Telephone: 212-639-2501; Fax: 212-794-7186; e-mail: saltzl{at}mskcc.org

Irinotecan (CPT-11, Camptosar), a semisynthetic, water-soluble derivative of the plant alkaloid camptothecin, is a drug which has undergone extensive clinical investigation worldwide. It is, at this time, commercially available in the United States for the treatment of fluorouracil-refractory colorectal cancer. In this review, I will discuss the current approved clinical use, discuss the issues of toxicity and its management, and consider some of the ongoing clinical investigations which are exploring possible future uses for this agent.

Key Words. Irinotecan • CPT-11 • Topoisomerase I inhibitor • Colorectal cancer




This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
M. Xie, D. Yang, L. Liu, B. Xue, and B. Yan
Human and Rodent Carboxylesterases: Immunorelatedness, Overlapping Substrate Specificity, Differential Sensitivity to Serine Enzyme Inhibitors, and Tumor-Related Expression
Drug Metab. Dispos., May 1, 2002; 30(5): 541 - 547.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
D. Yang, Y. Li, X. Yuan, L. Matoney, and B. Yan
Regulation of Rat Carboxylesterase Expression by 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD): A Dose-Dependent Decrease in mRNA Levels but a Biphasic Change in Protein Levels and Activity
Toxicol. Sci., November 1, 2001; 64(1): 20 - 27.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
W. Zhu, L. Song, H. Zhang, L. Matoney, E. LeCluyse, and B. Yan
Dexamethasone Differentially Regulates Expression of Carboxylesterase Genes in Humans and Rats
Drug Metab. Dispos., February 1, 2000; 28(2): 186 - 191.
[Abstract] [Full Text]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 1997 by AlphaMed Press.